1.Detection of Drug Resistance of Serratia Marcescens Rate Analysis and Carbapenemase
Xin WANG ; Chaojie REN ; Huizheng HU ; Xiaoke HAO
Journal of Modern Laboratory Medicine 2015;(1):118-120
Objective To analyze the drug resistance in clinical isolates of Serratiamarcescens of conventional treatment and carbapenemases,guiding the clinical rational drug use.Methods 106 strains of Serratiamarcescens from 2009~2012 year the clinical isolation,K-B disk diffusion susceptibility test,the modified Hodge method for screening the carbapenemase, Whonet statistical analysis.Results Serratia marcescens in sputum,secretions,swallow swab,urine samples were isolated 89 strains (84.1%),4 strains (3.8%),3 strains (2.8%)and 3 strains (2.8%).Serratiamarcescens resistant to ampicillin and cefazolin rate more than 90%,to aztreonam,cefepime,ceftazidime,piperacillin/tazobactam and Cefoperazone/sulbactam, drug resistance rate was 10%~22%,to amikacin,ciprofloxacin and imipenem were lower than 10%.Imipenem the resistant strains in 4 strains,the modified Hodge test positive 3 strains,the positive rate was 2.8%.Conclusion Serratiamarcescens extensively drug-resistant strains,the resistant mechanism is very complex,the institute has appeared carbapenemase produ-cing strains,clinicians should be based on the drug sensitivity test results.
2.Prader-Willi syndrome diagnosed in adulthood: A case report
Huizheng HU ; Xiaoguang SHI ; Jing LI ; Zhongyan SHAN
Chinese Journal of Endocrinology and Metabolism 2023;39(1):60-65
This article reports a case of Prader-Willi syndrome(PWS) diagnosed in adulthood. PWS is a rare genetic disease with most of the reported cases being diagnosed in infancy and childhood, and adulthood case is rarely reported. The patient had insidious symptoms in infancy and was diagnosed as PWS using genetic test in adulthood due to diabetes and menstrual disorders. This article focuses on the patient′s clinical manifestations in adulthood, and reviews relevant literature to improve the understanding of the disease.
3.Study on Chemical Constituents of n-Butanol Part from the Roots of Camellia oleifera
Fenghua WANG ; Qi REN ; Shourong HU ; Huizheng FU
China Pharmacy 2019;30(17):2369-2373
OBJECTIVE: To study the chemical constituents of n-Butanol part from the roots of Camellia oleifera, and to provide reference for elucidating the pharmacodynamic substance basis of it’s anti-tumor effect. METHODS: The ethanol extracts were obtained by using 95% ethanol as extraction solvent to extract the roots of C. oleifera, and the n-Butanol part was obatined after the extracts were extratced with ethyl acetate and water-saturated n-butanol solution in turn. The chemical constituents of n-butanol part were isolated and purified by D101 macroporous resin column, silica gel, atmospheric pressure reversed phase column chromatography, sephadex gel SephadexLH-20 column chromatogram and preparative HPLC. The structure of the compounds was identified by spectroscopic analysis of physicochemical constants, electrospray ionization mass spectrometry, 1H-NMR and 13C-NMR. RESULTS: Eight compounds were isolated from the roots of C. oleifera and elucidated as quercetin 3′ -O-β-D-glucoside (compound 1), apigenin-7-O-β-D-glucoside (compound 2), (+)-lyoniresinol-3α-O-β-D-glucopyranoside (compound 3), rubusoside (compound 4), dulcoside B (compound 5), 4-hydroxy-3-methoxyphenol 1-O-β-D-[6-O-(4-hydroxy-3,5-dimethoxylbenzoate)-glucopyranoside (compound 6), 3,4,5-trimethoxyphenyl-6-O- syringoyl-β-D-glucopyranoside (compound 7), gordonoside P (compound 8). CONCLUSIONS: Compounds 1-8 were isolated from this plant for the first time. This not only enriches the chemical constituents of this genus, but also provides a reference for elucidating the anti-tumor bioactive substances in this part.
4. Clinical outcomes of COVID-19 cases and influencing factors in Guangdong province
Yingtao ZHANG ; Aiping DENG ; Ting HU ; Xuguang CHEN ; Yali ZHUANG ; Xiaohua TAN ; Huizheng ZHEN ; Limei SUN ; Yan LI ; Haojie ZHONG ; Jianfeng HE ; Tie SONG ; Min KANG
Chinese Journal of Epidemiology 2020;41(0):E057-E057
Objective To analyze the clinical courses and outcomes of COVID-19 cases and the influencing factors in Guangdong province and provide basis for the formulation or adjustment of medical care and epidemic control strategy for COVID-19. Methods We collected demographic data, medical histories, clinical courses and outcomes of 1 350 COVID-19 patients reported in Guangdong as of 4 March 2020 via epidemiological investigation and process tracking. Disease severity and clinical course characteristics of the patients and influencing factors of severe illness were analyzed in our study. Results Among 1 350 cases of COVID-19 cases in Guangdong, 72 (5.3%) and 1049 (77.7%) were mild and ordinary cases, 164 (12.1%) were severe cases, 58 (4.3%) were critical cases and 7 (0.5%) were fatal. The median duration of illness were 23 days ( P 25 - P 75 : 18-31 days) and the median length of hospitalization were 20 days ( P 25 - P 75 : 15-27 days). For severe cases, the median time of showing severe manifestations was on the 12th day after onset ( P 25 - P 75 : 9th to 15th days), and the median time of severe manifestation lasted for 8 days P 25 - P 75 : 4-14 days). Among 1 066 discharged/fetal cases, 36.4% (36/99) and 1.0% (1/99) of the mild cases developed to ordinary cases and severe cases respectively after admission; and 5.2% (50/968) and 0.6% (6/968) of the ordinary cases developed to severe cases, and critical cases respectively after admission. In severe cases, 11.4% developed to critical cases (10/88). The influencing factors for severe illness or worse included male (a HR =1.87, 95% CI : 1.43-2.46), older age (a HR =1.67, 95% CI : 1.51-1.85), seeking medical care on day 2-3 after onset (a HR =1.73, 95% CI : 1.20-2.50) pre-existing diabetes (a HR =1.75, 95% CI : 1.12-2.73) and hypertension (a HR =1.49, 95% CI : 1.06-2.09). Conclusions The course of illness and length of hospitalization of COVID-19 cases were generally long and associated with severity of disease clinical outcomes. The severe cases were mainly occurred in populations at high risk. In the epidemic period, classified management of COVID-19 cases should be promoted according to needs for control and prevention of isolation and treatment for the purpose of rational allocation of medical resources.